J. Sukbuntherng

发表

Effect of CYP3A perpetrators on ibrutinib exposure in healthy participants

J. Murphy, J. Snoeys, R. de Vries, 2015, Pharmacology research & perspectives.

Ibrutinib Dosing Strategies Based on Interaction Potential of CYP3A4 Perpetrators Using Physiologically Based Pharmacokinetic Modeling

M. Monshouwer, L. D. De Zwart, J. Snoeys, 2016, Clinical pharmacology and therapeutics.

In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.

Juthamas Sukbuntherng, Robert A Blake, Guangmin Li, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Effects of ibrutinib on in vitro platelet aggregation in blood samples from healthy donors and donors with platelet dysfunction

T. Kinoshita, M. Crowther, A. Mokatrin, 2020, Hematology.

The effect of Bruton's tyrosine kinase (BTK) inhibitors on collagen‐induced platelet aggregation, BTK, and tyrosine kinase expressed in hepatocellular carcinoma (TEC)

T. Kinoshita, M. Versele, J. Sukbuntherng, 2018, European journal of haematology.

Properties Compared to R-Baclofen.

M. Gallop, J. Sukbuntherng, K. Koller, 2009 .

Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.

R. Advani, Sonali M. Smith, K. Kolibaba, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A drug–drug interaction study of ibrutinib with moderate/strong CYP3A inhibitors in patients with B-cell malignancies

D. Ouellet, L. D. De Zwart, J. Snoeys, 2018, Leukemia & lymphoma.

Absorption, Metabolism, and Excretion of Oral 14C Radiolabeled Ibrutinib: An Open-Label, Phase I, Single-Dose Study in Healthy Men

L. Leclercq, J. Murphy, J. de Jong, 2015, Drug Metabolism and Disposition.

Ibrutinib does not have clinically relevant interactions with oral contraceptives or substrates of CYP3A and CYP2B6

D. Ouellet, J. Jiao, J. de Jong, 2020, Pharmacology research & perspectives.

Simple apparatus for serial blood sampling in rodents permitting simultaneous measurement of locomotor activity as illustrated with cocaine.

J. Sukbuntherng, M. Mayersohn, A. Hutchaleelaha, 1997, Journal of pharmacological and toxicological methods.

Distribution, metabolism, and excretion of the anti-angiogenic compound SU5416.

Weiwei Tan, Qingling Zhang, S. Wong, 2006, Toxicology in vitro : an international journal published in association with BIBRA.

Evaluation of antitumor properties of novel saframycin analogs in vitro and in vivo.

P. Sabbatini, J. Eksterowicz, J. Sukbuntherng, 2006, Bioorganic & medicinal chemistry letters.

Pharmacokinetics and interspecies scaling of a novel VEGF receptor inhibitor, SU5416

G. Wagner, J. Sukbuntherng, A. Hannah, 2001, The Journal of pharmacy and pharmacology.

Open-Label Evaluation of ECG in Patients With Chronic Lymphocytic Leukemia (CLL) Receiving Ibrutinib Monotherapy

J. Sukbuntherng, D. Loury, F. Clow, 2013 .

Clinical pharmacokinetics of gabapentin after administration of gabapentin enacarbil extended-release tablets in patients with varying degrees of renal function using data from an open-label, single-dose pharmacokinetic study.

J. Sukbuntherng, Dan Chen, R. Lal, 2012, Clinical therapeutics.

Quantitative determination of cocaine, cocaethylene (ethylcocaine), and metabolites in plasma and urine by high-performance liquid chromatography.

J. Sukbuntherng, M. Mayersohn, H. Chow, 1995, Journal of pharmaceutical sciences.

Efforts toward oral bioavailability in factor VIIa inhibitors.

Liang Liu, C. O'bryan, E. Leahy, 2006, Bioorganic & medicinal chemistry letters.

Simultaneous determination of Z-SU5416 and its interconvertible geometric E-isomer in rat plasma by LC/MS/MS.

J. Sukbuntherng, Yeping Zhao, L. Antonian, 2004, Journal of pharmaceutical and biomedical analysis.

Disposition kinetics of d- and l-amphetamine following intravenous administration of racemic amphetamine to rats.

J. Sukbuntherng, M. Mayersohn, A. Hutchaleelaha, 1994, Drug metabolism and disposition: the biological fate of chemicals.

Factor VIIa inhibitors: a prodrug strategy to improve oral bioavailability.

Liang Liu, J. Mordenti, J. Sukbuntherng, 2006, Bioorganic & medicinal chemistry letters.

Small molecule inhibitors of plasma kallikrein.

B. Katz, J. Mordenti, J. Sukbuntherng, 2006, Bioorganic & medicinal chemistry letters.

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.

Juthamas Sukbuntherng, Susan O'Brien, Jeffrey A Jones, 2013, The New England journal of medicine.

Proof of target for SU11654: inhibition of KIT phosphorylation in canine mast cell tumors.

N. Pryer, Leslie B. Lee, J. Cherrington, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Pharmacokinetics and tolerability of single escalating doses of gabapentin enacarbil: a randomized-sequence, double-blind, placebo-controlled crossover study in healthy volunteers.

J. Sukbuntherng, Dan Chen, R. Lal, 2009, Clinical therapeutics.

The effect of food on the pharmacokinetics of oral ibrutinib in healthy participants and patients with chronic lymphocytic leukemia

J. Byrd, S. O'brien, J. Murphy, 2015, Cancer Chemotherapy and Pharmacology.

SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity

C. Liang, J. Cherrington, S. Vasile, 2006, Molecular Cancer Therapeutics.

Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies

Xavier Woot de Trixhe, J. Byrd, G. Nicolao, 2014, Cancer Chemotherapy and Pharmacology.

SU 14813 : a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity

C. Liang, J. Cherrington, S. Vasile, 2006 .

Ibrutinib does not prolong the corrected QT interval in healthy subjects: results from a thorough QT study

D. Ouellet, J. Jiao, J. de Jong, 2017, Cancer Chemotherapy and Pharmacology.

Characterization of the properties of cocaine in blood: blood clearance, blood to plasma ratio, and plasma protein binding.

J. Sukbuntherng, M. Mayersohn, Y. Pak, 1996, Journal of pharmaceutical sciences.

Ibrutinib Inhibits ERBB Receptor Tyrosine Kinases and HER2-Amplified Breast Cancer Cell Growth

Jun Chen, T. Kinoshita, J. Sukbuntherng, 2016, Molecular Cancer Therapeutics.

Evaluation of the safety and pharmacokinetics of the multi-targeted receptor tyrosine kinase inhibitor sunitinib during embryo-fetal development in rats and rabbits.

G. Chmielewski, J. Sukbuntherng, J. Haznedar, 2009, Birth defects research. Part B, Developmental and reproductive toxicology.

Separation and quantitation of the enantiomers of methamphetamine and its metabolites in urine by HPLC: precolumn derivatization and fluorescence detection.

J. Sukbuntherng, M. Mayersohn, A. Hutchaleelaha, 1995, Journal of analytical toxicology.

Arbaclofen Placarbil, a Novel R-Baclofen Prodrug: Improved Absorption, Distribution, Metabolism, and Elimination Properties Compared with R-Baclofen

M. Gallop, J. Sukbuntherng, K. Koller, 2009, Journal of Pharmacology and Experimental Therapeutics.

Stable isotope-labelled intravenous microdose for absolute bioavailability and effect of grapefruit juice on ibrutinib in healthy adults.

Juthamas Sukbuntherng, Jan Snoeys, L. D. De Zwart, 2016, British journal of clinical pharmacology.

Bioanalysis of ibrutinib and its active metabolite in human plasma: selectivity issue, impact assessment and resolution.

Naidong Weng, Philip Timmerman, Ronald de Vries, 2015, Bioanalysis.

The pH-altering agent omeprazole affects rate but not the extent of ibrutinib exposure

D. Ouellet, J. Jiao, J. Sukbuntherng, 2018, Cancer Chemotherapy and Pharmacology.

Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL.

J. Byrd, U. Jaeger, C. Dearden, 2017, Blood.

Single-dose pharmacokinetics of ibrutinib in subjects with varying degrees of hepatic impairment*

William Smith, T. Marbury, E. Lawitz, 2017, Leukemia & lymphoma.

Pharmacokinetics (PK) of ibrutinib in patients with chronic lymphocytic leukemia (CLL).

S. Chan, J. Sukbuntherng, D. James, 2013 .

Single- and multiple-dose disposition kinetics of sunitinib malate, a multitargeted receptor tyrosine kinase inhibitor: comparative plasma kinetics in non-clinical species

Qingling Zhang, J. Sukbuntherng, J. Haznedar, 2009, Cancer Chemotherapy and Pharmacology.

Population Pharmacokinetics and Pharmacodynamics of Gabapentin After Administration of Gabapentin Enacarbil

J. Sukbuntherng, R. Lal, W. Luo, 2013, Journal of clinical pharmacology.

Correction to: Ibrutinib does not prolong the corrected QT interval in healthy subjects: results from a thorough QT study

D. Ouellet, J. Jiao, J. Sukbuntherng, 2017, Cancer Chemotherapy and Pharmacology.

Abstract B19: Population pharmacokinetic-pharmacodynamic (PKPD) modeling of ibrutinib in patients with B-cell malignancies.

Michael L. Wang, J. Byrd, G. Nicolao, 2015 .

Clinical Evaluation of Xp19986 as a Potential Treatment for GERD: 25

J. Sukbuntherng, F. Huff, R. Lal, 2008 .

Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Results from the MRD Cohort of the Phase 2 CAPTIVATE Study.

I. Flinn, T. Kipps, S. Opat, 2019, Blood.

Clinical pharmacokinetic drug interaction studies of gabapentin enacarbil, a novel transported prodrug of gabapentin, with naproxen and cimetidine.

J. Sukbuntherng, R. Lal, W. Luo, 2010, British journal of clinical pharmacology.

A phase I, single-dose study of the disposition of 14C-radiolabeled gabapentin enacarbil in healthy male volunteers.

J. Sukbuntherng, R. Lal, K. Cundy, 2011, International journal of clinical pharmacology and therapeutics.

The effect of food with varying fat content on the clinical pharmacokinetics of gabapentin after oral administration of gabapentin enacarbil.

J. Sukbuntherng, F. Huff, R. Lal, 2010, International journal of clinical pharmacology and therapeutics.

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.

Jeffrey A Jones, J. Byrd, I. Flinn, 2013, The New England journal of medicine.

A drug–drug interaction study of ibrutinib with moderate/strong CYP3A inhibitors in patients with B-cell malignancies

D. Ouellet, J. Snoeys, J. Jiao, 2018, Leukemia & lymphoma.